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a1-Adrenergic receptors in rat renal microvessels. Although several
o-adrenergic receptor genes are expressed in the rat kidney, their expres-
sion in the renal vasculature has not been studied. Since pharmacological
studies have suggested that an a1-adrenergic receptor may mediate renal
vasoconstriction, we studied the expression of a10-adrenergic receptors in
renal microvessels, from 10- to 14-week-old male spontaneously hyperten-
sive rats (SHR) and their normotensive control, the Wistar-Kyoto rat
(WKY). In these microvessels, isolated by perfusion with iron, aiB-
adrenergic receptor mRNA levels (by ribonuclease protection assay) were
similar in SHR and WKY rats. Photo-affinity labeling with [I]-aiylazi-
doprazosin demonstrated the presence of a18-adrenergic receptor protein.
Maximum receptor density (determined by 3H-prazosin binding: Bm.,, 59.8
4.1 and 58.7 4.3; Kd 0.48 0.05 n and 0.31 0.06 nM in SHR and
WKY, respectively) and chloroethylclonidine(CEC)-sensitive binding sites
(determined by [12 I]-(2-/3(4-hydroxyphenyl)-ethylaminomethyl)-tetralone
binding) (1251-HEAT) were similar in SHR and WKY rats. There are two
novel findings in these studies: (1) the a1-adrenergic receptor gene is
expressed in renal microvessels of WKY and SHR; (2) a1-adrenergic
receptor gene expression in renal microvessels is not altered in adult SHR.
The failure to down-regulate expression of the a1-adrenergic receptor at
the mRNA and protein level in the SHR could result in persistence of
a1-adrenergic receptor effects and contribute to the increased vascular
resistance in hypertension.
Renal cross transplantation experiments have suggested that
the kidney plays a major role in the pathogenesis of genetic
hypertension [1—3]. Renal functional abnormalities common to
genetically hypertensive rats and to patients with essential hyper-
tension include increased renal vascular resistance [4], decreased
renal blood flow [51, renal-mediated sodium retention [6], and
increased adrenergic activity [7]. The increased adrenergic activity
may be due to increased norepinephrine released from renal
nerves, increased a-adrenergic density or increased a-adrenergic
effects [7, 8]. Genetic methods have identified that high blood
pressure and decreased renal blood flow, but not sodium reten-
tion, co-segregate through cross bred generations in spontane-
ously hypertensive (SHR) rats (Okamoto-Aoki strain) and Wistar
Kyoto rats (WKY) [9]. The lower renal blood flow in young may
be a reflection of increased sympathetic activity [71. Michel et al,
using renal homogenates that contained both vascular and tubular
tissue found no differences in the density or percent distribution
of renal a-adrenergic receptor subtypes in WKY and SHR [10].
Furthermore, norepinephrine-stimulated inositol formation in
renal membranes or cortical slices is similar or even decreased in
SHR compared to WKY [11, 12]. Although a-adrenergic recep-
tors have been studied in renovascular hypertension [13], there
are no studies that have compared a-adrenergic receptor density
or affinity in the renal vasculature of WKY and SHR. Indeed,
while Calianos and Muntz reported specific labeling with [3H]-
prazosin and [3H]-rauwolscine in rat kidney arterioles, significant
Scatchard analyses were not obtained and thus receptor affinity
and density could not be calculated [14].
Alpha1-adrenergic receptors have been pharmacologically clas-
sified into the alA and a1-adrenergic receptor [15]. The alA-
adrenergic receptor is insensitive while the a1-adrenergic recep-
tor is sensitive to alkylation by chloroethylclonidine (CEC) and
photo-affinity labeling by [1251]-arylazidoprazosin [15—17]. Molec-
ular biological techniques have identified several CEC-sensitive
a1-adrenergic receptor genes (ai, aic, and alA) (terminology
based on the 1995 Receptor Nomenclature) [18—261. The alA-
adrenergic receptor (formerly known as the alA, ac adrenocep-
tor) is now agreed upon to be product of the cloned aic-
adrenergic receptor gene; the alB adrenergic receptor remains to
be product of the cloned a1 adrenergic receptor; the aiD
receptor (formerly known as the alA/aiD) is the product of the
cloned a1 receptor gene [23]. These studies were therefore
designed (a) to obtain intrarenal microvessels from adult (10 to 14
weeks) WKY and SHR, and (b) to quantify a1-adrenergic receptor
subtype affinity and density in these vessels by [3H]-prazosin
binding. The pharmacologically defined a1-adrenergic receptor has
been thought to mediate the renal vasoconstrictor effect of adrener-
gic nerves [26—28]; however, the a1-adrenergic receptor may par-
ticipate in the response to exogenously administered adrenergic
agonists [29]. We, therefore, sought (c) to determine the presence of
a1-adrenergic mRNA by ribonuclease protection assay and a-
adrenergic protein expression by photo-affinity labeling with [1251]..
arylazidoprazosin as well as by CEC-sensitive [1I]-(2-/3(4-hydroxy-
phenyl)-ethylaminomethyl)-tetralone (1I-HEAT) binding [15].
Methods
Preparation of renal microvessels
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The protocols used in these experiments were approved by the
Georgetown University Animal Care and Use Committee. Ten- to
14-week-old male rats (WKY, mean arterial pressure 96 5 m
Hg and SHR mean arterial pressure = 150 2 mm Hg)
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of 1 to 2 mg/mI. Purity was determined by counting tubular
fragments and glomeruli under microscopic examination (we used
only preparations that were more than 90% free of tubular
contamination). The degree of purity of the vessel preparation
was further verified by determination of alkaline phosphatase
(present in tubules but not in blood vessels) and angiotensin
converting enzyme activity (present in both tubules and blood
vessels) [31, 32].
Radioligand binding studies
Fig. 1. Partial restriction map of the rat brain a1-adrenergic receptor
cDNA. Relevant endonuclease restriction sites are shown.
(Harlan-Sprague Dawley, Indianapolis, IN, USA) were anesthe-
tized with 50 mg/kg of pentobarbital given intraperitoneally. A
femoral artery was catheterized for blood pressure determination.
Renal microvessels were obtained according to the method de-
scribed by Everett et al [30] (see below). The rats were sacrificed
with 100 mg/kg body wt of pentobarbital given intravenously.
Membrane preparation for radioligand binding studies
One rat was used for each experiment; the number of experi-
ments in each protocol is indicated in the Results and Figure
legends. RPM! 1640 (Gibco, Life Tech Lab, Inc. Grand Island,
NY, USA) with L-glutamine with added glucose (5.5 mM) and
NaHCO3 (23.8 mM) was infused into the abdominal aorta until
the kidneys were clear of blood. Subsequently 20 ml of 1% ferrous
ferric oxide (Fisher Scientific Co., Pittsburgh, PA, USA) in RPMI
1640 was injected towards the kidney at a rate of 1.5 mi/mm. The
kidneys were removed and the cortex separated from the medulla.
The renal cortices were minced to a fine paste in the cold (4°C).
The minced tissue was resuspended in RPM! 1640 (20 ml/kidney)
with 0.5 mg/mI collagenase type IA (Sigma Chemical Co., St
Louis, MO, USA) previously bubbled with 95% 02 and 5% CO2
at 37°C in a shaker bath for 45 minutes to one hour or until free
vessels were seen. During this time, the suspension was vortexed
every 10 minutes. The microvessels were separated from non-
vascular tissue by a strong magnet. Glomeruli were separated
from the microvessels by passing the suspension through a 20 G
needle (3 X) and then through a 23 G needle (4 X). This
procedure separated the glomeruli and non-vascular tissue from
the microvessels. The suspension was then transferred unto a 106
sm sieve and washed thoroughly with a jet of ice-cold RPM! 1640
culture medium (20 ml). The microvessels retained in the sieve
were resuspended in ice cold RPM! 1640 and homogenized
(Polytron, setting 5, 30 seconds, x 3). The homogenate was
centrifuged at 200 X g for 15 minutes to remove iron oxide and
large pieces of arteries. The supernatant was pelleted by centrif-
ugation at 50,000 X g for 20 minutes. The pellet was resuspended
in incubation buffer (Tris-HC1, 50 mrvi, pH 7.5) at a concentration
Radioligand binding studies were performed as previously
described using 3H-prazosin (a1-adrenergic antagonist) or 25j
HEAT as the radioligands [14, 15]. Under standard assay condi-
tions, the incubate in a final volume of 1 ml, consisted of 0.8 ml
renal microvessel membranes in incubation buffer, 0.1 ml radio-
ligand, and 0.1 ml of incubation buffer alone or with unlabeled
ligands as indicated. The mixture was incubated at 25°C for 30
minutes in a Dubnoff shaking water bath. The reaction was
terminated by pouring the incubate over Whatman GF/C glass-
fiber filters in a Millipore sampling manifold under low negative
pressure as reported from our laboratory [33]. The incubation
tube was immediately rinsed 3 X with 3 ml of ice-cold incubation
buffer and poured over the same GF/C filters to wash away any
unbound radioactivity. The filters were subsequently collected
into polypropylene scintillation vials and radioactive decay was
measured in a Beckman LS-1801 liquid scintillation counter at an
efficiency of 60% using Liquiscint scintillation cocktail (National
Diagnostics, Atlanta, GA, USA) as the scintillation fluid. Specific
binding was defined as the difference between the amount of
radioligand bound in the absence (total binding) and presence
(nonspecific binding) of 10 1.LM phentolamine. The percent specific
binding of the radioligand at concentrations near the dissociation
constant (Kd) was generally >60%.
To determine both the Kd and the maximum number of specific
binding sites (BmJ of radioligand to microvessels (saturation
studies), six concentrations of radioligand were incubated with the
microvessels (0.01 tol.5 nM). The Kd and Bmax were calculated
from plots of the data according to Scatchard analyzed by
non-linear regression using the Lundon-1 Program (Lundon
Software, Inc., Cleveland, OH, USA). The ability of phentolamine
to compete with the specific binding of 3H-prazosin (30 to 80 pM)
was studied using 11 concentrations of the drug from i04 to
iO' M. The ability of WB-4101 to compete with the specific
binding of 1251-HEAT was also studied using 20 concentrations of
the drug from iO to 10_12 M.
CEC treatment
CEC, an alkylating analog of clonidine, variably but irreversibly
inactivates all the cloned a1-adrenergic receptors (ai > >
alA), the relative resistance of the a1-adrenergic receptor to
CEC has led to the suggestion that this may be the putative
a1-adrenergic receptor [15, 22—25]. Ribonuclease protection
assay using RNA from the whole kidney revealed expression of all
of these receptors (aic > > a) [25]. We also studied the
a1-adrenergic receptor protein subtype, for this the effect of CEC
on specific '251-HEAT binding was determined [15, 16]. In these
studies the membranes (4 ml aliquots) were incubated in 10 mM
Na 4-(2-hydroxyethyl)-1-piperazine-ethane sulfonic acid (Hepes),
pH 7.6 alone or with 30 .tM CEC for 10 minutes at 37°C [15]. The
reaction was stopped by diluting with 20 ml of cold Hepes buffer,
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Table 1. Enzyme markers for renal microvessels
Marker enzymes Rat strain
Crude
homogenate
Arterial
membrane
Fold change in
enzyme activity
Alkaline phosphatase WKY (N = 5) 858.49 43.25a 43.73 5.29a —20.18 2,04b
U/mg protein SHR (N = 5) 569.39 15.10 25.31 0.49 —22.53 0.90
Angiotensin converting enzyme WKY (N = 5) 0.032 0.005° 0.385 0.o6o + 13.36 3•94C
U/mg protein SHR (N = 5) 0.017 0.002 0.236 0.013 + 14.35 2.00
Data are mean SEM. The minus sign indicates a decrease, while the plus sign indicates an increase in enzyme activity. There were no differences
in the fold increase or decrease in enzyme activity, however, the specific enzyme activities were less in the SHR than in the WKY.
a P < 0.05
b, C No significant difference
3.0
2.0
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Bm, fmol/mg protein
Fig. 2. Scatchard plots of the specific binding of 3H-prazosin in renal arterial
microvessels in a representative experiment. The inset shows the dissociation
constant (K.) and maximum receptor density (Bm). Data are expressed
as mean standard error. There were no differences between SHR
(—.-—;N= 5)and WKY(----;N= 5)(P>0.05).
centrifuging at 20,000 X g for 10 minutes at 4°C. The pellet was
resuspended in 4 ml of 20 mrvi Na3PO4 buffer (pH 7.6) containing
154 mM NaC1. WB-4101, an a1-adrenergic receptor antagonist,
was used as the competing ligand. Low affinity binding sites
defined by WB-4101 was originally thought to represent am-
adrenergic receptors while the high affinity sites represent cloned
aic and a1-adrenergic receptors [15, 22—25].
Inhibition constants (K) were calculated using the Lundon-2
Program (Lundon Software, Inc.), which provides a non-linear
regression analysis of binding data as utilized by this laboratory
[33].
Photo-affinity labeling studies
Since the radioligand binding studies may not definitively
distinguish the a1- from the other adrenergic receptors, photo-
affinity labeling studies were performed using '251-arylazidopra-
zosin, Photo-affinity labeling with '251-arylazidoprazosin has been
demonstrated only for the cr1-adrenergic receptor [16, 22]. Renal
microvessels (0.15 to 0.20 mg) were incubated in the dark with 0.3
nM 1251-arylazidoprazosin [15] in a total volume of 500 1iA of buffer
(NaCI 150 mat, MgC12 1 mai, EGTA 2.5 mM,Tris-HC1 10 mM, pH
7.4 with 0.2 nat PMSF, 5 .tg/ml leupeptin, 5 g/ml pepstatin, 5
j.g/ml benzamidine) for 50 minutes at room temperature in the
presence or absence of 10 C.LM phentolamine to define non-specific
binding. After incubation, the samples were photolyzed for 15
minutes with UV light (365 nm) at 4°C. The samples were then
diluted with 500 1d of ice-cold buffer (with 1 mat glutathione),
centrifuged and prepared for SDS polyacrylamide gel electro-
phoresis (PAGE) as described below.
The photo-affinity labeled samples were washed twice with
buffer and resuspended in 50 to 60 p1 of SDS-PAGE buffer (NaC1
45 mM, MgC12 0.3 mM, EGTA 0.75 mist, SDS 4%, glycerol 10%,
13-mercaptoethanol 5%, Tris-HC1 65 mM, pH 6.7 with protease
inhibitors as above. After an overnight incubation at 22°C, the
SDS solubilized samples were subjected to electrophoresis on
polyacrylamide slab gel: a 4.5% upper stacking gel and 10% lower
separating gel were used. After completion of electrophoresis, the
gel was dried (Model 224; BioRad Labs., Richmond, CA, USA)
and autoradiographed with Kodak XAR-5 film with intensifying
screen at —80°C for two days. Molecular weights were determined
by graphically plotting the log of the molecular weight of known
protein standards versus the relative migration (Rf) of these
proteins. The apparent molecular weight (Mr) of photolabeled
receptors was estimated by determining the Rf (from the center of
the band) and interpolating the value on the standard curve.
RNA preparation
To determine further the presence of a1-adrenergic receptors
in renal microvessels, a18-adrenergic receptor mRNA was studied
by ribonuclease protection assay [34] (see below). Renal mi-
crovessels were obtained as described above with modifications.
Buffers were incubated with 0.1% DEPC (Sigma Chemical Co.) at
37°C overnight and then autoclaved to inhibit RNAse activity. In
addition, the buffers contained protease inhibitors (leupeptin 3
LM, PMSF 0.1 mat, DTT 0.5 mM; Sigma Chemical Co.). Further-
more, in order to eliminate RNase activity, all equipment were
incubated at 190°C for 12 hours. After obtaining the microvessels,
the samples were processed immediately to obtain RNA using the
method described by Chirgwin et al [34]. RNA, which was
quantified spectrophotometrically at 260 nm, was divided in
aliquots in TE buffer and frozen at —70°C until use.
-adrenergic receptor mRNA studies
A riboprobe was constructed using the rat brain eDNA encod-
ing a1-adrenergic receptor, provided by Dr. Hemin Chin; this
was digested with restriction enzymes Dral and PstI (bases 238 to
690) (Fig. 1) and subcloned in pGEM 7Z (pcmiic) [35]. palBlC was
Source Kd, flM 8max'
SHR (N =5) 0.48 0.05
WKY(N=5) 0.31 0.06
fmol/mg protein
59.8±4.1
58.7 4.3
0
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Fig. 3. A. Competition experiments between 3H-prazosin (30 to 80 pM) and
phentolamine in renal arterial microvessels. The data are the mean of 3
different experiments. Error bars are omitted for clarity (the SEM was less
than 10% of the mean value). Symbols are: () WKY treated with
phentolamine; (LI) SHR treated with phentolamine. B. Inhibition of
specific 1251-HEAT by WB-4101 in control and CEC-treated (30 M for 10
mm) renal arterial microvessels. Preparation of microvessels of WKY
without (•) and with (A) CEC pretreatment, and SHR with (t.) and
without (0) CEC pretreatment. Each value is the mean of triplicate
determinations from 4 experiments. Error bars are omitted for clarity (the
SEM was less than 10% of the mean value). The data were analyzed by
non-linear regression (see Methods).
linearized with Mlu I at a plasmid polylinker site. Sense or
antisense riboprobe was transcribed in vitro with a32P-CTP as
the limiting nucleotide using SP6 or T7 RNA polymerase
(MAXlscript, Ambion, Austin, TX, USA). The MIu I antisense
riboprobe was complementary to bases 238 and 690 of the original
eDNA sequence, and 100 bases of the plasmid DNA (78 bases
between the insert and the T7 RNA polymerase site and 22 bases
between the insert and the Mlu I site). Incorporation efficiency
fluctuated between 38 to 57% (67,000 to 79,000 cpmlpi, 6.7 x 108
to 8.13 x 108 cpm/.tg of newly synthesized RNA).
To determine the specificity of our probe and verify possible
differences in mRNA sampling of alB-receptor gene expression
between the SHR and WKY, we also studied the expression of
cyclophilin, a housekeeping gene. Thus, a cyclophilin antisense
riboprobe complimentary to bases 493 to 658 of the eDNA
sequence was transcribed; the incorporation efficiency was 32 to
37% (80,000 to 154,000 cpm/pl, 4.9 x 108 to 6.9 X 108 cpm/.tg of
newly synthesized RNA). The riboprobes were divided in aliquots
and frozen at —20°C until use (usually within 6 to 18 hr).
Ribonuclease protection assay
Varying amounts of RNA from renal microvessels were hybrid-
ized with the riboprobes at 44°C (RPA II, Ambion, Austin, TX,
USA) followed by RNase A/T1 digestion as previously reported
[36]. The protected hybrids were electrophoresed in 6% polyactyl-
amide-8 M urea gel and exposed to Kodak X-Omat AR at —70°C
for two to seven days. Sense riboprobe and yeast RNA were used
as negative controls.
Enzymatic, protein and statistical analyses
Protein concentrations were determined by the method of
Lowry et al [37]. Angiotensin converting enyme activity was
measured by the method of Hurst and Lovell-Smith [38]. Alkaline
phosphatase was measured using a procedure described by Bow-
ers and McComb [39] and Rej [40]. Results were expressed as
means 5EM. Significance was determined by Student's t-test or
one way analysis of variance with Scheffe's test for multiple
comparisons as indicated in the results. A P value < 0.05 was
considered as significant.
Materials
3H-prazosin (76.6 Ci/mmol), 1251-arylazidoprazosin (2200 Ci!
mmol) and 1251-HEAT (155 1iCi/ml) were purchased from Du-
pont-New England Nuclear (Boston, MA, USA). Phentolamine
and prazosin were gifts from Ciba-Geigy (Summit, NJ, USA);
Pfizer Labs (New York, NY, USA). Chlorethylclonidine and WB
4101 were purchased from Research Biochemicals Inc. (Natick,
MA, USA).
Results
In agreement with Everett et al, the microvessel preparations
were > 90% free of glomeruli and tubular tissue determined by
counting the number of tubules and glomeruli under microscopic
examination [30]. Angiotensin converting enzyme which is present
in blood vessels and tubules was enriched 13.36 3.94-fold in
WKY (N = 5) and 14.35 2.00-fold in SHR (N = 5) while
alkaline phosphatase, a marker for tubular contamination [31] was
decreased 20.18 2.04-fold in WKY and 22.53 0.92-fold in
SHR. There was no significant difference between the fold change
in enzyme activity between the SHR and the WKY. These data
show marked enrichment of microvessels (compared to crude
homogenate) which are essentially devoid of tubular contamina-
tion. Moreover, there were no differences in the purity of renal
microvessels between WKY and SHR. However, the specific
activity of these enzymes was higher in WKY than SHR (Table 1).
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Table 2. Effect of chioroethylcionidine (CEC) on receptor occupancy and inhibition constant determined by (1251)-heat binding in rat
renal microvessels
Dissociation constant
nM
Receptor occupancy
fmollmg protein
Receptor occupancy
%
Low High Low High Low High
affinity site affinity site affinity site affinity site affinity site affinity site
SHR N = 4
WKY N = 4
37.31 2.50
40.91 5.02
35.55 4.46
27.52 1.97
No CEC 44.92 17.7 0.15 0.05 6.99 0.96 11.45 1.08
With CEC 38.25 17.16 0.28 0.06 2.77 0.37a 439 1.15
No CEC 28.13 11.61 0.26 0.06 6.25 0.88 11.28 1.03
With CEC 41.88 13.04 0.32 0.11 1.96 0.38a 5.16 1.12
Data are mean SEM. N = number of rats. Specific binding was defined by 10 M phentolamine. WB-4101 was the competing ligand (see Fig. 3 for
range of concentrations used).
a P < 0.05 vs group not treated with CEC, ANOVA, Scheffe's test
62.69 2.50
59.09 5.14
64.45 4.46
72.48 1.97
decreased receptor occupancy (in fmol/mg protein, low affinity:
SHR from 6.99 0.96 to 2.77 0.37, WKY from 6.25 0.88 to
1.96 0.38; high affinity: SHR from 11.45 1.08 to 4.39 1.15,
WKY from 11.28 1.03 to 5.16 1.12, P < 0.05 ANOVA,
Scheffe's test) but did not change the affinity or the proportion of
high and low affinity binding sites. There were no differences in
affinity, receptor occupancy expressed in absolute amounts or
fractional occupancy, between SHR (N = 4) and WKY (N = 4).
Fig. 4. Representative experiment on the photo-affinity labeling of renal
microvessels from WKY and SHR. Non-specific binding was defined by 10
jM phentolamine. Arrow points to 77K band. Similar results were
obtained from two other experiments.
Radioligand binding studies
In both WKY and SHR, the binding of 3H-prazosin was
saturable with increasing ligand concentration. Non-linear regres-
sion analysis of the Scatchard plots (Fig. 2) revealed only one class
of binding site for 3H-prazosin in renal microvessels from both
WKY (N = 5) and SHR (N = 5). Bm was similar in SHR and
WKY (59.8 4.1 and 58.7 4.3 fmol/mg protein, respectively);
the Kd, however, was less in WKY (0.31 0.06) than in SHR (0.48
0.05 nM) (P < 0.05, t-test), indicating a higher affinity of
a1-adrenergic receptors in renal microvessels of WKY than SHR.
The ability of phentolamine, a non-selective a-adrenergic antag-
onist, to compete for specific 3H-prazosin was similar in WKY (N
= 3) and SHR (N = 3); only one affinity site was detected with
similar K (WKY = 12.0 0.82, SHR = 12.7 0.98) (Fig. 3A).
By contrast, the competitive binding curves between WB-4 101 and
1251HEAT were shallow and best fit two classes of binding sites:
a low and a high affinity site (Table 2, Fig. 3B). CEC significantly
Photo-affinity labeling studies
Photo-affinity labeling with '251-arylazidoprazosin has been
demonstrated only for the a1-adrenergic receptor [16, 22, 23]. To
determine any differences in M of a-adrenergic receptors in renal
microvessels from WKY and SHR, membranes were photola-
beled with 1251-arylazidoprazosin and the labeled products sub-
jected to SDS-PAGE (Fig. 4). The results are from one study
using microvessels from WKY and one study using microvessels
from SHR, which are representative of at least three different
studies for each rat strain. In renal microvessels, '251-arylazido-
prazosin labeled five polypeptide bands (94K, 77K, 40K, 31K and
25K) (lane labeled total). The ability of 10 JLM phentolamine (lane
labeled non-specific) to displace mainly the 77K band indicates
specificity of labeling of the a1-adrenergic receptor in agreement
with previous reports [17, 22, 41]. As in the radioligand binding
studies using 3H-prazosin or '251-HEAT, the photo-affinity la-
beled products using 1251-arylazidoprazosin were similar in WKY
and SHR (Fig. 4).
Alpha J-adrenergic receptor mRNA studies
To confirm the radioligand binding and photo-affinity labeling
studies that the a1-adrenergic receptor is present in renal
microvessels, the expression of the a1-adrenergic receptor gene
was determined by ribonuclease protection assay. An antisense
riboprobe was transcribed in vitro from a rat brain cDNA encod-
ing the a1-adrenergic receptor and hybridized with total RNA
obtained from microvessels. In preliminary studies, we found that
the minimum amount of total RNA needed per reaction was 40
xg and the minimum concentration of RNase AJT1 was 1:100
(data not shown). The use of Mlu I to linearize the plasmid
allowed the transcription of a probe of 553 bases and a protected
segment of 453 bases (Fig. 5). The bands were quantified by
densitometric analysis using QuantiScan (Biosoft, Ferguson, MO,
USA) as utilized by this laboratory [42]. In order to minimize
variability of the data, studies of WKY and SHR were always
Fig. 5. Ribonuclease protection assay.
Representative autoradiogram of aiB-
adrenergic receptor riboprobe (Mlu I) and
hybridized with RNA (50 jg total RNA) from
yeast or renal microvessels of WKY and SHR
in the presence or absence of ribonuclease.
The arrows point at the probe (553 bases)
and the protected band (453 bases) (similar
results were obtained with two other
experiments).
performed concurrently and the percent area of each blots was
quantified with the total area arbitrarily set at 100% [42].Densi-
tometric analysis of the bands did not reveal any difference
between WKY and SHR (48.4 7.2 vs. 51.7 7.2%, respectively;
N = 3). Alpha1-adrenergic receptor mRNA was also present in
glomeruli and proximal tubules (data not shown). In addition
using ribonuclease protection studies, under the same experimen-
tal conditions, we found similar amounts of mRNA of cyclophilin
(a housekeeping gene) in WKY and SHR (data not shown). The
two negative controls (sense riboprobe, data not shown, and yeast
RNA, Fig. 5) did not have any protected bands.
Discussion
Pharmacological data have shown the presence of a-adrenergic
receptors in the renal vasculature [4, 7], however, there has been
difficulty in demonstrating these receptors by radioligand binding.
For example, Calianos and Muntz reported the presence of
3H-rauwolscine and 3H-prazosin binding sites in rat renal arte-
rioles [14]; due to considerable variability in grain densities,
however, receptor affinity and density could not be analyzed [14].
Using a partially purified renal microvessel preparation (Table 1),
we have demonstrated the presence of saturable and specific high
affinity 3H-prazosin binding sites in rat intrarenal microvessels.
Since prazosin has a high affinity to the a1-adrenergic receptor, we
suggest that these sites represent a1-adrenergic receptors. Sub-
types of a1-adrenergic receptors may be present in these renal
microvessels since two affinity sites were defined by WB-4101. The
a1-adrenergic receptor and aJ-adrenergic receptor have a
higher affinity to WB-4101, compared to the a1-adrenergic
receptor [23]. The ability of CEC to decrease the receptor number
of both the high and low affinity sites indicates that all the cloned
a1-adrenergic receptors are present in these renal microvessels.
All of these receptors have been shown to be present in kidney
tissue [25, 26]. In situ hybridization detected only the aiD receptor
in blood vessels [43]. The failure to identify other a1-adrenergic
receptor could be explained by the lower sensitivity of the method
compared to ribonuclease protection assay. Whether the CEC
insensitive binding sites represent a1-adrenergic receptors could
not be determined since the concentration of CEC cannot com-
pletely inactivate the a1-adrenergic receptor [16, 22]. Neverthe-
less, the photo-affinity labeling studies and the demonstration of
a1-adrenergic receptor by ribonuclease protection assay clearly
demonstrate expression of this receptor gene in renal microves-
sels. The object of this study, however, was not to quantify all the
a-adrenergic receptor subtypes but rather to determine the
expression of a1-adrenergic receptors in renal microvessels and
compare their expression in WKY and SHR. Our interest in renal
vascular a1-adrenergic receptors lies in the report that this
receptor is involved in renal vasoconstriction [29].
A role of altered renal a-adrenergic receptors in genetic
hypertension has been suggested by some reports that increased
renal a-adrenergic receptors antedate blood pressure elevation in
the SHR [31. However, while more recent studies have confirmed
that a1- and a2-adrenergic receptor number are greater in SHR
than WKY, the increase did not precede blood pressure elevation
[11]. Moreover, cross breeding and cross transplantation experi-
ments have not supported a correlation between the density of
a1-adrenergic receptors or the ratio of the pharmacologically
defined a1- and a)-adrenergic receptor subtypes and systolic
blood pressure [10]. One limitation of these previous radioligand
binding studies is the use of whole kidney tissue which does not
distinguish renal tubular from vascular tissues. Indeed, Harrap
and Doyle reported that alterations in renal hemodynamics but
not sodium transport cosegregate with blood pressure elevation in
the SHR [91. In our studies using renal microvessels, no significant
differences in a1-adrenergic receptor density (determined by
3H-prazosin binding) could be detected between adult SHR and
WKY. There were also no significant differences in the number of
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a1-adrenergic receptor subtypes (defined by CEC sensitive WB-
4101 high affinity or low affinity binding sites). a18-adrenergic
receptor mRNA levels were also similar in WKY and SHR.
Although no functional studies were performed in our experi-
ments, other investigators have reported that basal and norepi-
nephrine-stimulated inositol phosphate formation is unchanged
or actually decreased in the SHR compared to WKY [11, 12],
possibly due to a higher affinity in WKY, as shown by the lower Kd
found in WKY. While increased reactivity of the renal vasculature
to vasoconstrictor agents has been reported in the SHR [4],
DiBona and Sawin have shown that the magnitude of the renal
vascular response to a1-adrenergic agonists is similar in normo-
tensive and spontaneously hypertensive rats [45]. Thus, our results
support the studies of DiBona et al and Michel et al showing that
renal a111-adrenergic receptors do not play a primary role in the
development of hypertension in the SHR [7, 8, 10—12, 44, 45].
Since renal nerve activity is enhanced [44] in the SHR, down
regulation of the a18-adrenergic receptor might have been antic-
ipated. The failure to down-regulate expression of the ajB-
adrenergic receptor at the mRNA and protein level in the SHR
could result in persistence of a1-adrenergic receptor effects and
contribute to the increased vascular resistance in hypertension.
In summary, our studies reveal two novel findings. One novel
finding is the demonstration that the a1 receptor gene is
expressed in renal microvessels of adult normotensive and hyper-
tensive rat. The other novel finding is the demonstration that the
expression of the cs receptor at the mRNA and protein level is
similar in adult WKY and SHR. Alterations in renal vascular
a18-adrenergic receptor gene expression do not seem to play a
primary role in the pathogenesis of hypertension in the SHR.
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